Ideas

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA 00152   inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 1/April/2019, 11,51 pm
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA 00152   inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 1/April/2019, 11,51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Intracardiac  injection of Cyclic helix B  peptide(CHBP) protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of Cyclic helix B  peptide(CHBP), a peptide derived from Erythropoietin/Hematopoietin, decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 1/April/2019, 11.33pm
Intracardiac  injection of Cyclic helix B  peptide(CHBP) protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of Cyclic helix B  peptide(CHBP), a peptide derived from Erythropoietin/Hematopoietin, decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 1/April/2019, 11.33pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

read more

 An aspirin a day keeps cancer away, if so, what is the mechanism?: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Aspirin, a nonsteroidal anti-inflammatory drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/April/2018, 11.19 pm
 An aspirin a day keeps cancer away, if so, what is the mechanism?: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Aspirin, a nonsteroidal anti-inflammatory drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 1/April/2018, 11.19 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: An aspirin a day keeps cancer away, if so, what…

read more

Intracardiac injection of Erythropoietin/Hematopoietin attenuates pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 31/March/2019, 9.29 am
Intracardiac injection of Erythropoietin/Hematopoietin attenuates pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 31/March/2019, 9.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am
Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more
Start Typing